The PROMISE III Trial

Clinical Trial Title

NCT05313165

National Clinical Trial Number:

The PROMISE III Trial: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

Contact Information

Karl Villanueva, MS, CCRP

Clinical Trial Protocol Description:

This study is for patients seeking treatment of chronic limb-threatening ischemia using the LimFlow System to provide additional information for creating an AV connection in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach to arterialize the pedal veins. 

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have a clinical diagnosis of chronic limb-threatening ischemia with ischemic ulceration or ischemic gangrene.

You will be excluded from the study if any of the following criteria apply to you:

  • Have severe heart failure, severe kidney disease, and/or those with active infection.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Study Details

Clinical Trial Investigator

Sreekumar Madassery, MD

Contact Information

Karl Villanueva, MS, CCRP

Clinical Trial Location

Rush University Medical Center

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more